1. Introduction
The relevance of the study of various types of cerebral pathology and the development of methods for their treatment does not require detailed justification [
1]. The World Health Organization defines human death as the death of the brain, which in life controls all the most important functions. In terms of prevalence and mortality, brain diseases rank third among diseases of the population of industrialized countries, lead not only to a decrease in life expectancy of the population, but also limit the social activity of a person due to the development of cognitive deficit, a decrease in the individual's ability to think, learn, adequately perceive information and make decisions [
2,
3]. In brain diseases of destructive and degenerative genesis, mitochondrial respiratory chain, energy metabolism, ionic homeostasis of the cell with increased content of calcium ions, development of glutamate excitotoxicity and damaging effect of nitrosative and oxidative stress, initiation of neuroapoptosis and cell death occur [
4]. The primary source of reactive oxygen species (ROS) is mitochondria, which play a key role in the cell's energy supply [
5]. Nowadays there is a generalized concept of “mitochondrial dysfunction”. This is a typical pathological process that has no etiologic and nosologic specificity. The development of mitochondrial dysfunction eventually leads to neuron death [
6]. We can speak about mitochondrial dysfunction as a new pathobiochemical mechanism of neurodegenerative disorders of a wide spectrum. All of the above is the rationale for the search for highly effective cerebroprotective drugs capable of preventing negative processes of mitochondrial dysfunction in the cell, thereby having a cerebroprotective effect [
7]. Currently, energy-tropic drugs such as coenzyme Q10, carnitine, B vitamins, succinic acid derivatives, etc. are being tried to correct mitochondrial dysfunction [
6,
8]. However, the rational basis for their use is poorly developed, and effective approaches are often underutilized or ineffective ones are overestimated. Medications are applied chaotically, without sufficient knowledge of their potential and characteristics, and without planning a treatment strategy from the perspective of appropriateness. Moreover, in cases of established mitochondrial dysfunction and the activation of apoptotic processes, these drugs are largely ineffective as they cannot regulate the subtle mechanisms of energy metabolism in which they act as intermediates.
Another approach to correcting mitochondrial dysfunction is also being considered: the use of thiol antioxidants. These compete with the SH-groups of the cysteine-dependent site of the mitochondrial inner membrane protein (ATP/ADP antiporter) for ROS and peroxynitrite, forming stable complexes with the latter. This prevents the opening of the mitochondrial pore under conditions of oxidative and nitrosative stress.
Particularly interesting and deserving of special attention is the use of drugs that act as ligands for neuropeptide receptors. These can regulate apoptosis, the expression of transcription factors, the synthesis of enzymes that regenerate mitochondrial DNA, and enzymes that catalyze energy reactions. Recently, significant efforts have been directed toward identifying highly effective neuroprotectors among neuropeptides.
The above highlights the scientific appeal of studying mitochondrial dysfunction in neurons, making the development of new approaches to pharmacological correction highly relevant and promising from the standpoint of comprehensive neuroprotection [
6,
9,
10].
1.1. The Role of Mitochondria in the Energy Metabolism of the Brain
The relationship between the structure and function of mitochondria remains a central focus of attention for a wide range of researchers. In recent years, revolutionary developments have taken place and are continuing in mitochondrial biology. Traditional views on the role of mitochondria in the cell have undergone significant revisions. Until relatively recently, our understanding of mitochondria was limited to their function as the cell's energy stations, and the role of mitochondria in the development of pathology was confined to energy supply disruption, with all ultrastructural changes in mitochondria being viewed exclusively from this perspective. However, many ultrastructural states of mitochondria cannot be explained within such frameworks. Today, there is no doubt about the crucial significance of mitochondria for the life of eukaryotic cells. The dominant role of these organelles in ATP production, the execution of programmed cell death processes, their involvement in the generation of reactive oxygen species (ROS), and the storage of calcium ions all determine their participation in the development of many pathological processes [
6,
11].
The brain has extremely high metabolic needs. It uses approximately 20% of the body's total oxygen and glucose consumption with only 2% of its body weight. About 70% of estimated energy expenditure is used to support neuronal signaling, including resting potentials, action potentials, postsynaptic receptor activation, glutamate cycling, and postsynaptic Ca2+ signaling , while the remainder goes to nonsignaling activities such as biomacromolecule trafficking, axonal transport, mitochondrial proton leakage, and actin cytoskeleton remodeling [
12,
13,
14].
Neurons exhibit the majority of energy consumption. They generate ATP primarily in mitochondria via oxidative phosphorylation, with a small portion of ATP from aerobic glycolysis in the cytoplasm. Astrocytes are highly glycolytic and convert glucose to lactate with low oxygen consumption; lactate is then delivered to neurons for complete oxidation. This process largely supports the energy requirements of neurons by supplying metabolic substrates [
15,
16].
Oligodendrocytes also obtain ATP mainly through aerobic glycolysis. They use lactate for their own energy needs and also supply neighboring axons with lactate. Microglia are mainly nourished by oxidative phosphorylation, but are metabolically reprogrammed to a phenotype dominated by aerobic glycolysis under certain neurological circumstances [
17,
18,
19]. Astrocytes have low mitochondrial activity of oxidative phosphorylation processes; this metabolic mode of astrocytes is essential for brain lipid homeostasis. Aberrant astrocytic oxidative phosphorylation process can cause accumulation of lipid droplets with subsequent development of neurodegeneration [
20].
1.2. Concept of Mitochondrial Dysfunction
To date, on the basis of experimental studies, the concept of mitochondrial dysfunction, its formation, molecular, biochemical and ultrastructural features has been formulated [
6,
21,
22,
23].
The development of mitochondrial dysfunction leads to the disruption of neurotransmitter reuptake (catecholamines, dopamine, serotonin), ion transport, impulse generation and conduction, de novo protein synthesis, translation and transcription processes; "parasitic" energy-producing reactions are activated, resulting in a significant depletion of the neuronal cell's energy reserves. Additionally, under the influence of reactive oxygen species (ROS), particularly the hydroxyl radical, mitochondrial pores are opened, leading to the expression and release of pro-apoptotic proteins into the cytosol. The opening of these pores occurs due to the oxidation of thiol groups in the cysteine-dependent region of the inner mitochondrial membrane protein (ATP/ADP antiporter), transforming it into a permeable nonspecific channel-pore. Today, the primary mechanism for this process is recognized as the formation of mitochondrial apoptotic pores and pores of increased permeability (РТP – permeability transition pores) [
6,
24,
25,
26,
27].
The opening of the giant pore makes the mitochondrial membranes permeable to dissolved substances with a molecular mass of 1500 Da and more. This disrupts mitochondrial metabolism, halting the synthesis of mitochondrial proteins and the import of proteins synthesized in the cytosol. Oxidative phosphorylation becomes uncoupled, and ATP synthesis stops. Hyperproduction of O2- begins, and reducing equivalents are depleted. The opening of the pore transforms the mitochondria from "power plants" into "furnaces" for oxidation substrates without ATP production [
28,
29].
It was found that interaction of mitochondrial structures with active derivatives of NO and ROS, Ca2+ “overbreathing” , reduction of intramitochondrial GSH enhances pore opening and release of apoptogenic proteins from damaged mitochondria [
30,
31]. In this context, the role of one of the neurotrophic factors, tumor necrosis factor-α (TNF-α), with which the opening of pores in mitochondria, the subsequent disruption of their membranes and the development of mitoptosis are associated, is significant [
32].
Thus, we can speak about mitochondrial dysfunction as a new pathobiochemical mechanism of neurodegenerative disorders of a wide spectrum. At present, two types of mitochodrial dysfunction are distinguished - primary as a consequence of congenital genetic defect and secondary, arising under the influence of various factors: hypoxia, ischemia, oxidative and nitrosative stress, expression of proinflammatory cytokines. In modern medicine, the doctrine of polysystemic disorders of cellular energy exchange, the so-called mitochondrial pathology, or mitochondrial dysfunction, occupies an increasingly important position [
6].
A key area of this section of medicine is hereditary syndromes based on mutations of genes responsible for mitochondrial proteins (Kearns-Sayre, MELAS, MERRF, Pearson, Barth, etc.) [
33].
However, the class of conditions characterized by mitochondrial dysfunction is by no means limited to these primary mitochondrial dysfunctions. A huge number of diseases include disorders of cellular energy metabolism - secondary mitochondrial dysfunctions as important links in pathogenesis. Among them: intracerebral hemorrhage, epileptogenic seizures, localized thermal brain damage, neurodegenerative disorders, transient cerebral ischemia, chronic fatigue syndrome, migraines, cardiomyopathies, alcoholic encephalopathies, senile dementia, neuroinfections, cardiomyopathies, glycogenoses, connective tissue diseases, diabetes, rickets, tubulopathies, pancytopenia, hypoparathyroidism, liver failure, and many others (
Figure 1) [
6].
The study of these disorders is of particular importance for practical medicine due to the availability of effective therapeutic correction methods. However, it should be noted that the range of pathological disruptions in cellular energy metabolism is extremely wide (damages to various links in the Krebs cycle, respiratory chain, beta-oxidation, etc.). Mitochondrial dysfunction is closely associated with the hyperexpression of early genes, such as c-fos. In conditions of reactive oxygen species (ROS) hyperproduction by the neurochemical and bioenergetic systems of the brain during brain ischemia, as well as in several other neurodestructive pathological processes, there is an activation of the expression of redox-sensitive genes, many of which are essential for protecting cells from the toxic effects of oxidative stress [
34,
35,
36].
Thus, under normal oxygen concentration in the surrounding cell environment (normoxia), the activation of JunB and ATF-2 transcription factors mainly occurs under the action of ROS, while under oxidative stress, the activation of c-Jun and c-fos factors predominates. The activation of these specific transcription factors under conditions of ROS hyperproduction is explained by the fact that JunB and c-fos contain cysteine residues (Cys252, Cys54, Cys61) in their DNA-binding domains that are highly sensitive to ROS. Oxidation of their SH-groups leads to the reverse inactivation of AR-1 and NF-kB [
6,
37,
38].
In addition, c-fos protein is directly involved in the process of mitochondrial DNA fragmentation and initiation of apoptotic neuronal cell death. c-fos is responsible for NO hyperproduction in neurodegenerative diseases through iNOS activation. c-fos is one of the main nuclear targets for signaling regulation of cell growth and transformation, and is involved in many cellular functions, including cell proliferation and differentiation processes [
39,
40,
41].
It is currently known that the main manifestations of mitochondrial dysfunction are a decrease in ATP levels in the cell, activation of cell death mechanisms, and the production of ROS by the mitochondria. It is known that during the functioning of the mitochondrial respiratory chain, small amounts of superoxide radical (O
•–2) are formed as a byproduct of the respiratory complexes [
42,
43].
4. Mitochondrial Dysfunction and Apoptosis
The activation of neuroapoptosis, according to many researchers, is the primary cause of persistent cognitive and mnemonic dysfunctions in the central nervous system (CNS). Neuroapoptosis develops as a cascade process accompanied by the activation (induction of formation) of specific pro- or anti-apoptotic proteins, as well as specialized proteolytic enzymes—caspases. Among the factors triggering apoptosis, the formation of reactive oxygen species (ROS) during the "distorted" pathway of oxidative metabolism in the cell should be noted. Convincing evidence exists that mitochondria play a central role in ROS production and the subsequent development of apoptosis and necrosis. This involves changes in the permeability of mitochondrial membranes due to the formation of specific mitochondrial pore complexes and the initiation of mitoptosis (
Figure 3) [
175,
176].
Under the influence of hydroxyl radicals, mitochondrial pores open, leading to the expression and release of pro-apoptotic proteins into the cytosol. The opening of these pores transforms mitochondria from "power plants" into "furnaces" for oxidation substrates without ATP production. Precise biochemical studies have established that disruptions in tissue oxygenation, hyperproduction of excitotoxic amino acids, a decrease in "normal" Ca²⁺ accumulation by mitochondria, and oxidative damage to mitochondrial membranes by reactive oxygen species (ROS) exacerbate pore opening and the release of apoptogenic proteins from damaged mitochondria.
In this context, the role of one neurotrophic factor—tumor necrosis factor-α (TNF-α)—is significant. TNF-α is associated with the opening of mitochondrial pores, subsequent membrane damage, and the progression of mitoptosis. The mitochondrial pore is a channel traversing both mitochondrial membranes and comprises three proteins: the adenine nucleotide translocator, the voltage-dependent anion channel (porin), and the benzodiazepine receptor. When this complex binds to Ca²⁺, substances with small molecular masses can pass through the membrane pore. This process leads to a decrease in membrane potential and matrix swelling, which inevitably compromises the integrity of the outer membrane. Consequently, apoptosis-related proteins are released from the intermembrane space into the cytoplasm [
177,
178].
There are several of them: APOptosis-inducing factor, secondary mitochondria-derived activator of caspases (Smac) and some procaspases. The inducing factor goes directly to the nucleus, where it causes DNA degradation. Along with specific apoptosis proteins, cytochrome C, which normally serves as the final link in the electrotransport chain, leaves the mitochondrion through the open pore. In the cytoplasm, this protein binds to the protein Apaf-1 (APOptotic protease activating factor-1) and forms an apoptosome complex. It, with the help of Smac and another factor (Omi/HtrA2), activates procaspase-9, which, becoming caspase-9, transforms two other proenzymes into caspases-3 and 7; and they already cleave structural proteins, leading to the appearance of biochemical and morphological signs of apoptosis [
179,
180,
181]. Among the earliest events, in particular, are the translocation of phosphatidylserine to the outer membrane layer and DNA fragmentation under the influence of ROS and NO [
182].
Among the secondary signs, the most characteristic are the "shedding" of the cell from the matrix, membrane wrinkling, nuclear condensation, and the formation of vesicles containing cellular contents—apoptotic bodies [
183]. The release of cytochrome c into the cytoplasm is facilitated by a decrease in pH during the development of lactate acidosis and an increase in oxidative modification of mitochondrial proteins and lipids. This latter reaction is directly triggered by ROS, which are inevitably formed as a result of "parasitic" energy reactions [
184]. Cytochrome C can be released in response to an increase in Ca²⁺ ion concentration, which triggers pore opening, and its release is also regulated by proteins of the Bcl-2 family [
185,
186].
They are the ones that regulate apoptosis at the mitochondrial level. Some of the proteins of this large family (Bcl-2, as well as Bcl-xL, Bcl-w, Mcl-1, Al, and Boo) prevent apoptosis; others (Bax, Bad, Bok, Bcl-xS, Bak, Bid, Bik, Bim, Krk, and Mtd) promote its initiation [
187,
188].
The entire superfamily of Bcl-2-related proteins is considered to be one of the most important classes of apoptosis-regulating gene products. Their ever-expanding list includes both cell death antagonists and apoptosis-inducing proteins. Due to the large number of representatives of this family described to date, they are usually divided into three groups [
189,
190].
1- Anti-apoptotic proteins Bcl-2, Bcl-xL, Bcl-w, Mcl-1, Bfl-1 and Boo with homology in the BH1, 2, 3 and 4 regions.
2. Pro-apoptotic proteins Bax, Bak, Bad, Bok and Diva with homology in regions BH1, 2 and 3 but not BH4.
3. "BH3-proteins" are pro-apoptotic proteins such as Bik, Bid, Bim, Hrk, and Blk, which share homology exclusively in the BH3 domain.
The combined action of related cell death agonists and antagonists from the Bcl-2 family represents a regulatory switch whose function is determined, at least in part, by selective protein-protein interactions. These proteins are characterized by the ability to form heterodimers in which partners repress each other [
191].
Proapoptotic proteins are mostly localized in the cytosol and translocate to the mitochondrial membrane in response to certain stimuli. Some studies claim that Bach proteins translocate from the cytosol to the mitochondria, while others suggest that they undergo conformational changes enhanced by interaction with Bid proteins [
192].
Bid proteins are known to be hydrolyzed by caspase-8 and their C-terminal part interacts with mitochondria. Several models have been proposed for the participation of Bcl-2 family proteins in the regulation of protein transfer from the mitochondrion to the cytosol [
193,
194,
195].
1. Since Bax (like other Bcl-2 family proteins) can form pores in the outer mitochondrial membrane, it has been hypothesized that these pores might be large enough to allow cytochrome c to exit. However, this has not yet been confirmed.
2. There is a hypothesis suggesting that Bax interacts with VDAC, resulting in the formation of an even larger channel capable of accommodating cytochrome C. Notably, the conductivity of this channel is blocked by Bcl-xL [
196].
3. Bcl-2 can also form channels in the outer mitochondrial membrane that allow adenine nucleotides to pass through. It is hypothesized that Vach closes VDAC, ATP/ADP exchange between mitochondrion and cytoplasm is disrupted, resulting in the opening of RTR. Moreover, all these phenomena are prevented by Bcl 2 [
197,
198,
199].
4. There is also a hypothesis that suggests that the Bcl-2 family protein complex interacts with the giant pore complex in the inner mitochondrial membrane and leads to membrane depolarization, mitochondrial swelling, and cytochrome С release [
200,
201].
The Bcl-2 protein has a direct inhibitory effect on pore opening, but it does not protect against all permeability change inducers. Because the mitochondrial pore is regulated by a complex that includes Bcl-2 and Bax antagonists, changes in its stoichiometry (e.g., increased Bax synthesis or Bcl-2 modification) may contribute to permeability changes. It is hypothesized that the ratio between Bcl-2 and Bax proteins, and their phosphorylation, promotes either cell survival (excess Bcl-2 or Bcl-xL) or cell death (excess Bax, phosphorylation of Bcl-2). At the level of phosphorylation, there is a link between changes in mitochondrial permeability and receptor signaling pathways, as phosphorylation can be produced by protein kinases such as JNK (activated by various stress stimuli and through TNFR and Fas receptors, phosphorylates Bcl-2) and PKB/Akt, which transmits signals of growth factors NGF, IGF-1, phosphorylates Bad, preventing apoptosis [
202,
203,
204,
205,
206,
207,
208].
Bcl-2 acts as a neuroantioxidant - it blocks the output of cytochrome C and prevents the development of apoptosis. Protein 53 (p53) takes part in triggering apoptosis caused by DNA damage, activation of oncogenes and hypoxia by interacting with Vach, stimulating “death receptors” and apoptosis genes. p53 activates the suicide modulator PUMA (p53 upregulated modulator of APOptosis), which then binds Bcl-2 and disables this protein that prevents apoptosis. Thus, the release of cytochrome C from mitochondria is no longer restrained by anything [
109,
209]
Some calcium ion-binding proteins, such as ALG-2, encoded by the gene of the same name (APOptosis-linked gene-2), also participate in the development of neuroapoptosis. Thus, the interaction between ALG-2 and the Alix protein (ALG-interacting protein X, also known as AIP1) regulates neuroapoptosis [
210,
211,
212].
It is assumed that in addition to the participation of dysfunctional mitochondria in apoptosis processes, they play a key role in the cell's choice of a pathway to realize the type of morphological death. Data from various researchers indicate that activation of the mechanisms of one or another form of cell death pathway may be determined by the number of open pores in dysfunctional mitochondria. If pores are formed in several mitochondria, the autophagy process is activated in the cell [
213,
214,
215,
216]. When pores open in more dysfunctional mitochondria, apoptosis is initiated in the cell, which is probably a consequence of an increase in cytochrome C and apoptosis induced factor (AIF) in the cytoplasm. Eventually, when PT pores open in the cell in almost all dysfunctional mitochondria, dissociation of oxidation and phosphorylation and intensive ATP hydrolysis by mitochondrial ATPase occur, the mechanisms of necrosis-like cell death are activated [
217,
218,
219,
220]. In dysfunctional mitochondria the minimum number of open pores does not fundamentally affect the process of cell death, and with a larger number of open pores the initiation of apoptosis is possible, with generalized opening of mitochondrial pores the process of necrosis is realized [
221,
222,
223]. The level of ATP production in dysfunctional mitochondria is of great importance in the “choice” between the realization of apoptosis and necrosis-like programmed cell death. At low ATP level in dysfunctional mitochondria the process of programmed cell death by necrosis mechanism proceeds, sufficient energy supply promotes the process of programmed cell death by apoptosis mechanism [
224,
225,
226,
227,
228].
5. Possible Strategies for Pharmacocorrection of Mitochondrial Dysfunction
It is shown that the development of mitochondrial dysfunction is naturally accompanied by damage to brain matter [
229,
230,
231]. The following ways of possible pharmacologic correction of mitochondrial dysfunction are currently postulated [
6,
232,
233,
234,
235,
236,
237].
1) increase in the efficiency of mitochondria use of deficient oxygen due to prevention of dissociation of oxidation and phosphorylation, stabilization of mitochondrial membranes;
2) weakening of inhibition of Krebs cycle reactions, especially by maintaining the activity of succinatoxidase link;
3) compensation of the lost components of the respiratory chain;
4) formation of artificial redox systems that shunt the electron overloaded respiratory chain;
5) economization of oxygen utilization and reduction of oxygen demand of tissues or weakening of respiratory control in mitochondria, or inhibition of pathways of its consumption that are not necessary for emergency maintenance of vital activity in critical states (non-phosphorylating enzymatic oxidation - thermoregulatory, microsomal, etc., non-enzymatic oxidation of lipids);
6) increase in ATP formation during glycolysis without increasing lactate production;
7) reduction of ATP consumption by the cell for processes that do not determine emergency maintenance of vital activity in critical situations (various synthetic reductive reactions, functioning of energy-dependent transport systems, etc.);
8) introduction of high-energy compounds from outside.
Today, there is no drug that would influence all the above-mentioned ways of correction of energy metabolism. At present, in order to correct mitochondrial dysfunction and energy deficiency, mainly antihypoxants are used - agents that improve the body's absorption of oxygen and reduce the brain's need for it, thereby contributing to the body's resistance to oxygen deficiency. From the biochemical point of view, hypoxia is a violation of substrate oxidation in the tissues of the body due to the impediment or block of electron transport in the respiratory chain, so the action of antihypoxants should be realized at the cellular level and be directed at the respiratory chain. To date, there is no single established classification of antihypoxants. This is due to the fact that the drugs are represented by compounds from different chemical classes and the mechanism of their action is not always studied. They can improve the oxygen transport function of blood or preserve the energy status of the cell under hypoxia. Direct energizing action of antihypoxants is aimed at correction of respiratory chain function under hypoxia conditions. In addition, there are antihypoxants of nonspecific action, the effects of which are aimed at the correction of functional-metabolic systems [
238,
239,
240,
241].
Currently, the mechanism of action of known antihypoxants is aimed at the following links of cell energy metabolism and includes drugs of different pharmacological groups:
1. Electron carriers in the respiratory chain (coenzyme Q10 and its analog idebenone, succinic acid, vitamins K1, K3);
2. cofactors of enzyme reactions of energy metabolism (nicotinamide, riboflavin, L-carnitine and others);
3. correctors of lactate acidosis (dimefosfon).
Clinical and experimental studies of the last decade have established that in the acute period of ischemic stroke, pharmacological correction of energy supply should include restoration of electron-transport and conjugating function of the NAD-dependent part of the respiratory chain, as well as activation of compensatory metabolic mechanisms providing electron delivery to the cytochrome section of the chain [
6,
242,
243,
244]
5.1. Idebeon
Idebeon is an original drug of quinone structure, is a derivative of ubiquinone (coenzyme Q) Idebeon has reduced hydrophobicity, ability to penetrate the blood-brain barrier, activates the respiratory function of mitochondria and has a positive effect on the processes of free-radical oxidation in brain tissue. Under the conditions of in vitro experiment in nervous tissue culture it was shown that idebenone prevents the formation of free radicals in cytosol and mitochondria, while in parallel reducing the concentration of marker products of oxidative modification of protein molecules. Idebenone is able to act as an electron carrier in the respiratory chain of mitochondria, increases the formation of ATP, and also increases glucose utilization in nervous tissue, in parallel, reducing the likelihood of lactate acidosis development [
245,
246,
247]. In clinical trials, idebenone has demonstrated the ability to improve memory and learning ability in ischemic brain damage. The effectiveness of idebenone in multi-infarct dementia was confirmed by the results of multicenter studies. In cerebrovascular insufficiency of various degrees of severity, a course of therapy with idebenone at a dose of 90 mg/kg resulted in some improvement of cognitive functions after 1.5-2 months of treatment. The efficacy of idebenone in complex therapy of such primary mitochondrial dysfunctions as MELAS syndrome, Leber's optic atrophy, Ley's disease has also been shown [
248,
249,
250].
5.2. Menadione
Menadione or 2-methyl-1,4-naphthoquinone can be incorporated into the respiratory chain and by shunting the electron flow at the site from NADH KoQ, restores the electron flow to cytochrome oxidase under hypoxia. Menadione administration to nerve cell cultures under conditions of moderate hypoxia has been shown to normalize NADH/NAD , increase mitochondrial respiration rate, and increase ATP concentration. Menadione Nrf2-dependent activation of gene expression followed by enhanced formation of protective proteins such as enzymes involved in glutathione biosynthesis [
251,
252,
253]. Menadione was considered as a promising mitochondrial antioxidant and mitoprotector [
6]. However, higher concentrations of menadione cause toxic oxidative stress associated with tissue damage, mitochondrial DNA damage, and cell death [
254]. Menadione can undergo one-electron reduction, resulting in the formation of unstable free radicals that produce reactive oxygen species by rapid reaction with oxygen, thereby causing oxidative stress. However, other studies have shown that menadione is an effective inhibitor of lipid peroxidation in microsomes by suppressing lipid peroxide formation through various mechanisms, including binding to one-electron molecule transfer enzymes. According to other studies, reduced forms of menadione may exhibit antioxidant activity [
255]. All of the above requires additional studies.
Synthetic ubiquinone-containing preparations from the class of redox polymers, among which Sodium polydihydroxyphenylene thiosulfonate - olifen (hypoxen) has gained popularity, contribute to the restoration of respiratory chain functioning.
5.3. Olifen
Olifen has a polyphenolic ubiquinone component in its structure, contributes to the reduction of electron leakage from the respiratory chain and exhibits antihypoxic and antioscidatic properties. Under conditions of oxygen deficiency the use of oliphene is accompanied by oxidation of reduced nicotinic and flavinic nucleotides. It prevents the development of lipoperoxidation reactions of mitochondrial suspension membranes, preserves the charge of the outer mitochondrial membrane, stimulates the destruction of peroxidation products [
6]. Olifen is used in the manifestation of secondary mitochondrial dysfunction due to chronic myocardial ischemia and working hypoxia, due to physical overload. It shows actoprotective effect [
256,
257]
5.4. Succinic Acid
To enhance the alternative NADH-oxidase pathway of ATP formation, agents involved in succinatoxidase oxidation are used, the stimulation of which is achieved by activation of succinate dehydrogenase reaction through exposure to succinate-containing compounds that facilitate the transport of succinate into the cell. Succinate exerts its antihypoxic effect in two ways. First, it acts as a substrate of the tricarboxylic acid cycle and the enzyme succinate dehydrogenase. Second, it plays a role as a signaling molecule, activating HIF-1α and the orthologous receptors SUCNR1 and GPR91. Interaction with the latter promotes an increase in the level of reabsorbed glucose and stimulation of gluconeogenesis [
258,
259,
260]. The combination of sodium succinate and cytochrome C is promising from the point of view of energetotropic and anti-ischemic action. Sodium salts of succinate are effective in reducing metabolic intracellular acidosis due to intracellular oxidation with the replacement of one hydrogen molecule by sodium to form bicarbonate. Antioxidant action of succinates is realized due to inhibition of production of reactive oxygen species by bioenergetic reactions of mitochondria. Antioxidant effect of succinate is manifested in the reduction of oxidative stress products, in particular carbonylated proteins in the susceptibility of mitochondria of myocardium and brain of experimental animals. Activates the synthesis of endogenous antioxidant - glutathione. Stimulates erythropoiesis. Increases the level of adrenaline, noradrenaline and dopamine, due to which psychostimulant, normotimic and antidepressant effects are observed. The efficacy of the drug containing succinate has been shown in secondary mitochondrial dysfunctions caused by myocardial ischemia, chronic cerebral ischemia and working hypoxia [
261]. The possibility of using succinic acid preparations in primary mitochondrial dysfunction is actively discussed, particularly in a patient with MELAS syndrome [
262,
263]. Combination succinate-containing drugs such as reamberine, cytoflavin, and remaxol have found use in clinical practice [
261,
264,
265]. The bioavailability of succinate is enhanced by combining it with various metabolites (such as citric and malic acids). Salts of succinic acid and mixtures, such as Limontar (a combination of sodium succinate and citric acid), are more readily accessible to mitochondria and are oxidized within them. A more promising approach today involves increasing the activity of succinate dehydrogenase and stimulating endogenous succinate production. This is achieved through pharmacological agents that act as succinate precursors and improve its penetration through the blood-brain barrier. However, such drugs have not yet found application in clinical medicine, and research in this area is currently limited to experimental studies [
6,
266,
267].
Cytochrome C and KoQ preparations may be recommended in later stages of hypoxia as a redox mediator of the respiratory chain at the site between flavoprotein dehydrogenase and cytochromes stabilizes mitochondrial inner membranes, relieves succinate oxidase and NADH-oxidase inhibition [
268,
269,
270]
In the 1960s–1970s, under the leadership of Academician V. Skulachev, a class of mitochondrial antioxidants was developed under the general name SkQ. To deliver antioxidants to mitochondria, a low-molecular-weight compound was proposed, consisting of a positively charged phosphorus atom surrounded by three hydrophobic phenyl groups (triphenylphosphonium, TPP, a charged triphenylphosphine). The mitochondrial protective properties of compounds combining TPP with ubiquinone and TPP with plastoquinone (a quinone involved in the electron transport chain during photosynthesis) were studied.
Currently, 11 compounds of this type are known: SkQ1, SkQR1, SkQ2, SkQ2M, SkQ3, SkQ4, SkQ5, SkQBerb, SkQPalm, C12TPP, and MitoQ. Plastiquinone derivatives with one, two, or three methyl groups are used as the antioxidant component. SkQR1 is considered the most active.
The mechanism of the mitochondrial protective action of such compounds involves their penetration into mitochondria and the reduction of reactive oxygen species (ROS). This occurs both by decreasing ROS production during mitochondrial bioenergetic reactions and through direct interaction between SkQ compounds and ROS [
271,
272,
273,
274,
275].
No less important drugs in conditions of cerebral hypoxia will be the so-called “correctors of lactate acidosis”. These medications include dimefosfon.
5.5. Dimefosfon
Dimefosfon is a dimethyl ester of 1,1-dimethyl-3-oxobutyl phosphonic acid. Dimefosfon had pronounced antihypoxic and anti-ischemic properties. The antihypoxic effect of dimefosfon was associated with a decrease in lactate production in brain structures simultaneously with an increase in the activity of key cellular energy supply enzymes: NADPH (diaphorase, succinate dehydrogenase and glycero-6-phosphate dehydrogenase), accompanied by an increase in ATP and creatine phosphate. Dimefosfon increased brain energy charge by decreasing oxygen consumption by brain tissue. Dimefosfon inhibits lipoperoxidation processes of mitochondrial meebras isolated from rat hippocampal neurons. It is active in relation to secondary mitochondrial dysfunction caused by cerebral ischemia. It is known to be a positive modulator of neuronal acetylcholoesterase. [
6].
However, despite the accumulated large clinical material on the use of the above-mentioned drugs, at present, they do not fully meet all the requirements for drugs correcting mitochondrial dysfunction. Thus, clear criteria and principles of their combined use, as well as the possibility of their use at different stages of bioenergetic hypoxia have not been developed. In addition, drugs are used chaotically, without sufficient knowledge about their capabilities, as well as without planning the treatment strategy from the position of expediency. In addition, a significant disadvantage of modern antihypoxants and neuroprotectors is their inability to affect the delicate molecular and biochemical chains of energy metabolism at already formed mitochondrial dysfunction, as well as their ineffectiveness with respect to the processes of cell death [
6,
276,
277].
In this regard, another approach to correcting mitochondrial dysfunction is currently being considered—the use of antioxidant drugs that, by acting on the cell's antioxidant system, reduce the concentration of cytotoxic marker products of oxidative destruction of proteins and nucleic acids. Through this effect, antioxidants can restore energy production in the mitochondrial respiratory chain and mitigate mitochondrial dysfunction, given the well-known role of reactive oxygen species (ROS) in its development.
However, it is important to emphasize that the use of antioxidant drugs is often inconsistent, and dosing regimens for these drugs are not clearly established. This can lead to a situation where antioxidants begin to act as pro-oxidants within cells.
In this context, so-called "thiol antioxidants," which contain free SH-groups in their molecular structure, are of particular interest. According to several researchers, the presence of SH-groups allows thiol antioxidants to compete with ROS, forming "stable complexes" with them, thereby protecting the SH-groups in the cysteine-dependent region of mitochondrial inner membrane proteins. This action of antioxidants helps prevent the opening of mitochondrial pores under conditions of oxidative and nitrosative stress [
6,
278,
279].
Recently, the thiol antioxidant N-acetylcysteine (NAC) has attracted the attention of pharmacologists and clinicians.
5.6. NAC (N-Acetylcysteine)
NAC acts as a "trap" for peroxynitrite and nitric oxide (NO), suppresses the production of IL-1β, and inhibits the activity of H₂O₂-dependent p38 stress kinases in astrocytes. It has been established that NAC, indirectly through the reduction of ROS levels, inhibits the functioning of the MAP kinase cascade, thereby decreasing the production of transcription factors. This, in turn, reduces the expression of genes responsible for the synthesis of NO synthase and COX-1 in astrocyte cultures [
280,
281,
282].
It should be noted, however, that studies on the activity of NAC have been conducted predominantly in vitro and on model pathologies associated with brain ischemia, where it demonstrated relatively low therapeutic efficacy. Among other antioxidants, derivatives of hydroxypyridine—emoxypine and its succinate salt, mexidol—have found practical applications.
5.7. Emoxypine and Mexidol
Emoxypine and mexidol are highly effective inhibitors of free radical oxidation and suppress oxidative protein modification in ischemic brain tissue. Both drugs exhibit pronounced membrane-stabilizing effects (increasing the content of phosphatidylserine and phosphatidylinositol) and normalize the activity of various membrane-dependent enzymes, such as adenylate cyclase and creatine phosphokinase [
6,
283,
284].
5.8. Ethylmethylhydroxypyridine Succinate
Ethylmethylhydroxypyridine succinate (Mexidol, Mexicor) is widely used today as an antioxidant and antihypoxant. It activates compensatory metabolic processes by facilitating succinate entry into the mitochondrial respiratory chain, thereby enhancing the energy-producing function of mitochondria, improving energy metabolism, and maintaining the levels of macroergic compounds under conditions of mitochondrial insufficiency.
Mexidol inhibits lipid peroxidation and increases the activity of antioxidant enzymes, such as superoxide dismutase and glutathione peroxidase, due to its 3-hydroxypyridine component. Additionally, Mexidol modulates the activity of membrane-associated enzymes (adenylate cyclase, acetylcholinesterase, etc.), neurotransmitter transport systems, ion channels, receptors, and receptor complexes (such as acetylcholine and GABA).
It also has the ability to reduce glutamate excitotoxicity and nitric oxide (NO) levels, while regulating the expression of early-response genes such as c-fos and HIF-1mRNA [
285,
286].
Mexidol exerts a protective effect on the protein components of neuronal membranes, including receptors and ion channels, enhancing nerve conduction and synaptic transmission. It stimulates the energy-producing functions of mitochondria and ATP synthesis. Mexidol has been shown to improve the ultrastructure of myocardial mitochondria following ischemia and reperfusion.
In experimental studies, Mexidol alleviated cognitive deficits in animals during the recovery period after total brain ischemia, under conditions of emotional-pain stress, and following the administration of cholinomimetics. Mexidol demonstrated good therapeutic efficacy in the treatment of carotid stroke, promoting regression of neurological and cognitive deficits, normalizing EEG patterns, and showing no significant side effects [
6,
287].
Mexidol is used mainly in secondary mitochondrial dysfunctions accompanying chronic cerebral ischemia, CNS damage due to prenatal hypoxia, multiple sclerosis, working hypoxia [
264,
288]. In primary mitochondrial dysfunctions mexidol was used as part of complex therapy of MELAS syndrome and in mitochondrial myopathy [
6,
289].
5.9. Meldonium
Meldonium (mildronate) is a metabolitotropic cardioprotector. The main mechanism of its action is reversible inhibition of the rate of carnitine synthesis from its precursor - γ-butyrobetaine, which leads to a decrease in carnitine-mediated transport of long-chain fatty acids without changing the metabolic processes of short-chain fatty acids through mitochondrial membranes, i.e. there is no complete blockage of oxidation of all fatty acids [
6,
290]. Meldonium in secondary mitochondrial dysfunction due to myocardial ischemia, working hypoxia, cardiomyopathy after prenatal hypoxia, cerebral ischemia [
291,
292,
293]. There have been attempts to use meldonium for the treatment of primary mitochondrial dysfunction, particularly MELAS syndrome [
6].
The thiol antioxidant and ROS/NO scavenger Thiotriazoline has gained wide international recognition. It was first synthesized in the USSR, specifically at the Zaporizhzhia Medical University in 1982, and became an original pharmaceutical drug in Ukraine in 1992.
Thiotriazoline enhances the energetic potential of the myocardium and mitigates oxidative stress in conditions such as ischemic heart disease, physical overexertion, and work-related hypoxia [
6].
5.10. Thiotriazoline
Thiotriazoline (tiazotic acid (thiotriazoline) The results of numerous studies have shown the ability of thiotriazoline to influence oxidative processes in mitochondria in ischemic lesions of the brain and heart (
Figure 4). Thus, it was found that the anti-ischemic efficacy of the drug is based on its ability to reduce the degree of inhibition of oxidative processes in the Krebs cycle, activate the compensatory malate-aspartate shuttle mechanism and increase the production of ATP and ADP against the background of a decrease in AMP [
294]. Under conditions of ischemic brain injury, Thiotriazoline normalizes glucose utilization within cells, increases the activity of glucose-6-phosphate dehydrogenase, restores the NAD/NADH ratio and cytochrome C oxidase activity, and elevates the levels of pyruvate, malate, isocitrate, and succinate. Simultaneously, it reduces lactate overproduction, mitigates uncompensated acidosis, and counters its pro-oxidant effects. Thiotriazoline is the only drug known to activate the conversion of lactate to pyruvate
In both in vitro and in vivo studies, Thiotriazoline inhibited mitochondrial ROS production. As a nitric oxide (NO) scavenger, it enhances NO bioavailability. Moreover, it prevents the irreversible inactivation of the NF-kappa B transcription factor by protecting cysteine residues—Cys 252, Cys 154, and Cys 61—in its DNA-binding domains from excessive ROS. Thiotriazoline also appears to facilitate the restoration of these residues during reversible inactivation, acting in the role of Redox Factor-1.
Preincubation of mitochondrial suspensions with Thiotriazoline (10⁻⁵ M) and subsequent addition of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (60 μM), sodium nitroprusside (100 μM), or H₂O₂ (50 μM) significantly inhibited the rate of mitochondrial pore opening (p≤0.05), increased mitochondrial membrane potential (p≤0.05), and raised intramitochondrial GSH concentration (p≤0.05).
Thiotriazoline preserves the threshold sensitivity of membrane receptors, maintains membrane fluidity, protects phospholipids from oxidation, prevents ion channel polarization, and normalizes ion transport. Additionally, Thiotriazoline inhibits NO-dependent apoptotic mechanisms and increases levels of the anti-apoptotic [
6].
Our studies have established that tiotriazolin is effective in secondary mitochondrial dysfunction due to myocardial ischemia, cerebral ischemia, working hypoxia after exercise, and intrauterine hypoxia. And also congenital mitochondrial dysfunction leading to myocardial hypertrophy in children [
149,
295,
296,
297,
298,
299].
5.11. Angiolin
It has been established that in cases of already developed mitochondrial dysfunction and the initiation of apoptotic processes, metabolic therapy agents (such as coenzyme Q10, carnitine, B vitamins, and succinic acid derivatives) demonstrate limited efficacy and are unable to regulate the delicate aspects of energy metabolism for which they serve as intermediates (
Figure 5).
Another approach to correcting mitochondrial dysfunction involves the use of thiol antioxidants. These agents compete with the SH-groups of cysteine-dependent sites on the inner mitochondrial membrane protein (ATP/ADP antiporter) for reactive oxygen species (ROS) and peroxynitrite, forming stable complexes with the latter. This mechanism prevents the opening of mitochondrial pores under conditions of oxidative and nitrosative stress.
This foundation led to the development of a fundamentally new metabolitotropic endothelial protector with an original structure—((S)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate), named "Angiolin". Angiolin exhibits anti-ischemic, cardioprotective, neuroprotective, and antioxidant properties [
295,
300,
301,
302].
The mitochondrial protective effect of Angiolin was established. Pre-incubation of the mitochondrial suspension with Angiolin (10-5 M) and the addition of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (60 μM) significantly inhibited the rate of mitochondrial pore opening (p≤0.05) and increased the mitochondrial membrane potential (p≤0.05). Additionally, it elevated the intramitochondrial concentration of HSP70 (p≤0.05) and reduced (p≤0.05) the number of damaged mitochondria compared to control samples [
6].
Angiolin (100 mg/kg) is effective in secondary mitochondrial dysfunction following chronic cerebral ischemia and intrauterine hypoxia. Angiolin significantly reduced the number of damaged mitochondria in CA1 hippocampal neurons and increased the intramitochondrial concentrations of HSP70 and GSH [
300,
303,
304].
5.12. Benzodiazepines
Recent studies have shown that the manifestations of mitochondrial dysfunction in CNS ischemic lesions can be reduced by regulating the opening of mitochondrial pores. Given that the mitochondrial pore contains a regulatory benzodiazepine receptor, benzodiazepine receptor modulators deserve attention. Among them, the derivatives of 1,4-benzodiazepine and 1,3,4-benzotriazepine are of the greatest interest, as they have a wide range of neurotropic activities: antidepressant, antihypoxic, and nootropic effects. However, the effect of these drugs on mitochondrial functional activity during brain ischemia has not been studied, which defines the potential for further research in this area [
305,
306,
307,
308]. Pre-incubation of the mitochondrial suspension with a benzodiazepine receptor modulator (cinazepam, 10-5 M) and the addition of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (60 μM) showed a weak inhibitory effect on the rate of mitochondrial pore opening, increased the mitochondrial membrane potential, and slightly increased the intramitochondrial concentration of HSP70. However, it did not significantly affect the number of damaged mitochondria compared to the control samples [
6].
5.13. Estrogens and Selective Estrogen Receptor Modulators.
It is known that, alongside their effects on the reproductive system, estrogens have a multifaceted impact on higher brain functions. It has been shown that estradiol plays a key role in the prenatal and early postnatal development of the brain, as well as throughout life in various disorders of the hypothalamic-pituitary-ovarian system. The main mechanism of estrogen action is genomic, which occurs at the level of the cell nucleus; the non-genomic mechanism exerts its effect through the cell membrane. To implement genomic effects in the brain, there are two types of receptors – estrogen receptor α (ERα) and estrogen receptor β (ERβ).
Tamoxifen and livial, which are anti-estrogens for breast tissue, exert their anti-estrogenic action through the activation of corepressors. Conversely, tamoxifen and livial, being agonists for endometrial cells, exhibit estrogenic effects through the stimulation of coactivators, while livial has no effect on endometrial cells [
309,
310,
311,
312].
Different concentrations of adapter proteins in estrogen-sensitive cells determine the selectivity and agonist/antagonist nature of tamoxifen and livial. It has been established that tamoxifen and its metabolite can inhibit the neurotoxic glutamate system and exert neuroprotective effects in β-amyloid-induced amnesia [
313,
314]. Experimental studies have established a rather high neuroprotective efficiency of estrogen receptor modulators in conditions of deprivation of the glutathione link of the thiol-disulfide system in the suspension of isolated neurons. Such an effect of estrogen receptor modulators, in our opinion, is explained, first, by their direct antioxidant effects. Secondly, it is known that estrogen receptor activation involves uncoupling of estrogen receptors from heat shock proteins (hsp), which ensures the penetration of HSP70 inside the cell.
Thirdly, it has been established that selective estrogen receptor modulators modulate the expression of global transcription factors, particularly AP-1, which is responsible for the synthesis of key enzymes in the antioxidant and thiol-disulfide systems. This explains the significant ability of tamoxifen and livial to restore the activity of superoxide dismutase, glutathione S-transferase, and glutathione reductase. Additionally, the anti-apoptotic effect of estrogens has been noted, which is due to the stimulation of the expression of anti-apoptotic proteins from the Bcl-xL family. Thus, our results reveal the importance of the neuronal glutathione system as a key target for neuroprotective therapy and provide experimental justification for the clinical use of estrogen receptor modulators—tamoxifen and livial—as neuroprotective agents. Tamoxifen is effective in secondary mitochondrial dysfunctions resulting from cerebral ischemia. Our experimental studies have established the neuroprotective activity of the selective estrogen receptor modulator tamoxifen citrate, which occurs, firstly, due to its ability to increase the levels of Hsp70 proteins in the brain tissue during the acute phase of ischemia. Secondly, tamoxifen citrate is capable of limiting the development of oxidative and nitrosative stresses, leading to a reduction in the concentrations of homocysteine and nitrotyrosine in the brain and an increase in glutathione, thus restoring thiol-disulfide balance in nerve cells. The synergistic enhancement of these effects of tamoxifen citrate under acute cerebral ischemia conditions led to a pronounced neuroprotective effect—reducing mortality and neurological deficit [
315,
316].
5.14. Neuropeptides
Currently, the search for neuroprotective and energy-tropic drugs of HSP-mediated action is conducted among neuropeptides capable of increasing HIF-protein concentration by modulating the expression of global transcription factors [
149].
The discovery of neurotrophic peptide factors, prompted the formation of a new strategy of pharmacotherapy - peptidergic, or neurotrophic therapy of neurodegenerative diseases [
317,
318]. A new class of neuroprotective agents has been created on the basis of peptide preparations. The ideology of creating these drugs is based on the recognition of the role of neuropeptides as universal “integrators” that unite and coordinate the activities of the three main regulatory systems of the organism - nervous, endocrine and immune systems [
319].
A number of drugs with neurotrophic properties have been developed that are successfully used in the therapy of a wide range of neurological disorders. Cerebrolysin, Cerebrocurin, Cortexin, Semax, which have been successfully used in the clinic of neurological disorders for ten years already, have been the most successful (
Figure 6) [
6,
320]. Among the presented drugs, a special place is occupied by the domestic neuropeptide drug – cerebrocurin, which includes amino acids, neuropeptides, as well as low-molecular-weight products of controlled proteolysis of proteins and peptides from cattle embryos. The mechanism of action and targets of cerebrocurin are fundamentally different from other neuropeptide drugs, particularly from cerebrolisin. Cerebrocurin contains peptides that carry a program for analyzing the state and construction of the CNS. Thus, the final effect differs due to the qualitatively different mechanism of action. In addition, cerebrocurin increases the affinity of BDNF for its receptors. When cerebrocurin was administered to animals with cerebral ischemia, an increase in ATP production in oxidative reactions in the brain (cortex, CA1 hippocampus) was observed, as evidenced by an increase in malate content, enhanced activity of mitochondrial malate dehydrogenase, and cytochrome C oxidase. Cerebrocurin not only affected energy production but also its transport and utilization, as indicated by the increase in the activity of mitochondrial and cytoplasmic creatine phosphokinase. An important aspect of cerebrocurin's effect on energy metabolism under brain ischemia conditions was the significant reduction in lactate production and lactate acidosis. Through the regulation of early response gene expression (c-fos) and the anti-apoptotic protein bcl-2, cerebrocurin is able to influence neuroapoptosis processes to some extent in cerebral ischemia conditions. The reduction of mitochondrial dysfunction in the context of ischemic brain pathology and the normalization of neuronal energy metabolism upon cerebrocurin administration contributed to the preservation of the main morphofunctional characteristics of neurons in the sensorimotor cortex during cerebral ischemia. Pre-incubation of the mitochondrial suspension with cerebrocurin and the addition of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahidropyridine) (60 μM) significantly inhibited the rate of mitochondrial pore opening, increased the mitochondrial membrane potential, and elevated the intramitochondrial concentration of HSP70. Moreover, it had a significant effect on the number of damaged mitochondria compared to control samples [
6,
321].
Experimental studies have revealed that cerebrocurin prevents microglia hyperactivation and reduces the production of IL-1α and other pro-inflammatory cytokines, reflecting the drug's impact on the severity of local inflammatory reactions and processes. Cerebrocurin is effective for pharmacocorrection of both primary mitochondrial dysfunction (MELAS, MERRF) and secondary mitochondrial dysfunction, especially as a result of cerebral ischemia, intrauterine hypoxia, and ischemic opticopathy [
322,
323,
324,
325]. These neuropeptide drugs have also been successfully utilized in the management of various comorbid conditions, including hypertension, thyroid pathology, alterations in microbiota, chronic kidney disease, pregnancy, osteoarthritis, and type 2 diabetes mellitus [
326,
327,
328,
328,
330,
331]. Their broad therapeutic potential highlights their applicability across a diverse spectrum of systemic and metabolic disorders [
332,
333,
334,
335,
336].
Author Contributions
Conceptualization, I.B., O.P., N.B., V.R., S.P., E.S., V.O. and O.K.; validation I.B., O.P., N.B., V.R..; writing—review and editing, I.B., O.P., N.B., V.R., S.P., E.S., V.O. and O.K.; visualization, I.B., O.P., S.P., E.S., V.O. and O.K.; supervision I.B., O.P., N.B., V.R., S.P., E.S., V.O. and O.K.. All authors have read and agreed to the published version of the manuscript.